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SUMMARY
Pattern recognition receptors are the main sensors of the innate immune response. Their function is to recognize pathogen-
associated molecular patterns, which are molecules essential for the survival of microbial pathogens, but are not produced
by the host. The recognition of pathogen-associated molecular patterns by pattern recognition receptors leads to the expression
of cytokines, chemokines, and co-stimulatory molecules that eliminate pathogens, such as viruses, for the activation of antigen
presenting cells and for the activation of specific adaptive immunity. Among the most thoroughly studied pattern recognition
receptors implicated in viral infections, there are the toll-like receptors (TLRs) and the RNA helicase-type retinoic acid-
inducible gene-1 receptors [or RIG-like receptors (RLRs)]. Moreover, other proteins such as PKR, 2’-5’ OAS, and ADAR
also act as effector proteins in antiviral responses. The identification and characterization of pattern recognition receptors have
contributed to our knowledge of the role of innate immunity in viral infections and has led us to better understand host-
pathogen interactions. The most recent findings concerning the role of TLRs and RLRs in viral infections, the molecular
mechanisms of viral ligand recognition through pattern recognition receptors, and the activation of their signaling pathways
are discussed in this review.
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Reconocimiento viral por el sistema inmune innato: papel de los receptores de reconocimiento de patrones
RESUMEN
Los receptores de reconocimiento de patrones (PRR) son los principales sensores de la respuesta inmune innata. Su
función es reconocer moléculas indispensables para la sobrevivencia de los patógenos, conocidas como patrones moleculares
asociados a patógenos (PAMP). El reconocimiento de los PAMP por los PRR conlleva a la expresión de citoquinas,
quimioquinas, y moléculas coestimuladoras implicadas en la eliminación de patógenos como virus, en la activación de células
presentadoras de antígenos y en la inducción de una inmunidad adaptativa específica. Entre los PRR mejor descritos y con
implicaciones en infecciones virales se encuentran los receptores tipo toll (TLR) y receptores tipo RNA helicasas inducibles
por ácido retinoico (RLR); además las proteínas efectoras PKR, 2´- 5´ OAS y ADAR también participan activamente en la
respuesta antiviral. La descripción y caracterización de los PRR ha contribuido enormemente al entendimiento del papel de
la respuesta inmune innata en las infecciones virales y han sido usados para comprender mejor las interacciones hospedero-
patógenos. Se discuten en la presente revisión los más recientes conocimientos de los TLR y  RLR, el mecanismo  de
reconocimiento de los virus vía PRRs y las vías de señalización activadas por dicho reconocimiento.
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Innate immunity is the first protecting barrier of the
host against foreign agents; its response and quality
determine the development of adaptive immunity
responses. The activation of the innate immune response
involves a wide spectrum of cells and soluble factors
that recognize and exert effector functions when
challenged by pathogens that can enter the host.
However, it was the description of pathogen recognition
receptors (PRRs) and, particularly, of Toll-like receptors
(TLRs) that led to understanding the prominent role
that innate immunity plays in the recognition of microbial
pathogens and in the regulation of the immune system1.
Table 1














TLR2 Hemagglutinin protein of the Varicella virus
herpes Simplex virus-1
human cytomegalovirus
TLR4 syncytial respiratory virus














TLR9 Synthetic CpG-containing DNA
vesicular Stomatitis Virus
murine Cytomegalovirus
herpes Simplex Virus -1 and 2
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Figure 1. PRRs and antiviral proteins of the innate immune response. Viral nucleic acids and some viral
proteins are recognized by TLRs, RLRs and DAI, which induce a signaling pathway that activates the
production of cytokines and type-I IFN. IFN-mediated signaling through its cellular receptor IFNAR
induces the expression of several proteins with antiviral activity. In addition, the IFN induced by virus
infection can bind to specific cell receptors and trigger the expression of different genes such as PKR. PKR
is activated through homodimerisation after binding to viral dsRNAs via its dsRNA domain.  Once active,
as a kinase, PKR phosphorylates eIF2α (eIF2 αp) and blocks synthesis of both cellular or viral proteins. 2’5
‘OAS and Mx GTPase are two additional effector pathways of the IFN-mediated antiviral response.  The
first is activated by dsRNA and specifically activates the latent form of RNase L leading to RNA
degradation, and the second is activated by viral proteins and blocks viral transcription.  On the other
hand, TRIM 5α recognizes the viral capsid core and blocks HIV-1 infection at a post-entry, pre-integration
stage in the viral life cycle.
One of the most interesting aspects of innate
immunity is the wide range of molecules recognized by
PRRs. These receptors recognize diverse structural
components or ligands (Table 1)2, essential for the
survival of microorganisms, known as pathogen-
associated molecular patterns (PAMPs)2. Recognition
of PAMPs by PRRs stimulates an intracellular signaling
cascade that involves the activation of diverse trans-
criptional factors involved in regulating expression of
cytokines. Such cytokines play important roles in host
protection, in the activation and migration of antigen
presenting cells, and in the induction of the adaptive
immune response.
This review will focus on certain signaling PRRs
that are potent triggers of inflammatory responses and
play a very important role in viral infections. Among
them there are the TLRs that can be either endosomal or
extracellular3,4, and retinoic acid-inducible gene-
(RIG-) I/MDA5 (melanoma differentiation-associated
gene 5), known as RNA helicase-like receptors (RLRs).
Furthermore, Double-stranded RNA-dependent protein
kinase (PKR), 2',5'-oligoadenylate synthetase (2’-
5’OAS), and adenosine deaminase acting on RNA
(ADAR), known as effector proteins, complement the
function of PRRs1. All these proteins are the main
sensors of viral components and induce pro-
inflammatory cytokine expression or interferon (IFN)
response factors (Figure 1). This review discusses
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recent new knowledge on the molecular mechanism
and role of PRRs in the recognition of viral PAMPs, the
signaling pathways activated by such recognition, as
well as the strategies used by viruses to evade such
response.
TLRs, adaptor molecules and their signaling
pathways. TLRs are the best characterized members of
the PRR family and can recognize both intracellular
and extracellular pathogens4. Ten TLRs have been
described in humans and all are type-1 membrane
glycoproteins, from which six (TLR2, 3, 4 7/8, and 9)
recognize viral components (Table 1). Some TLRs
form hetero (TLR2/TLR1, TLR2/TLR6) or homo-
dimers5. TLRs have an ectodomain or extracellular
domain with leucine-rich repeats (LRRs), a trans-
membrane region and a cytoplasmic domain,
homologous to the interleukin-1 (IL-1) receptor, known
as Toll/IL-1R (TIR)3.
Briefly, the signaling pathway induced by TLRs is
as follows: each TLR is stimulated by its specific
ligand, which is recognized through the ectodomain.
This leads to the recruitment, through the TIR, of
adaptor proteins like the myeloid differentiation primary
response protein 88 (MyD88), the Toll/IL-1 receptor
domain containing adaptor protein (TIRAP), the Toll/
IL-1 receptor domain containing adaptor inducing
interferon-beta (TRIF), and the TRIF-related adaptor
molecule (TRAM) (Figure 2). The IL-1R associated
protein (IRAK) and tumor necrosis factor (TNF) recep-
tor-associated factor 6 (TRAF6) then also participate in
the signaling pathway. TRAF6 acts as an ubiquitin
ligase E and activates the transforming growth factor
(TGF) β-activated kinase 1 (TAK1) complex and its
subunits the TAK1-binding protein-(TAB) 1 and TAB2/
3, responsible for the phosphorylation of NF-kappaB
essential modulator (NEMO), which results in the
Figure 2. Viral recognition through TLRs and the RIG-I protein. TLR2 and 4 recognize mainly viral envelope
proteins and recruit MyD88 by an adaptor (Mal) protein; TLR7 and TLR9 interact directly with MyD88
following ligand recognition (viral ssRNA and viral DNA, respectively). In contrast, TLR3 recognizes the
presence of dsRNA through the recruitment of TRIF. Following MyD88 or TRIF recruitment, a signaling
pathway is initiated via RIP1/TRAF6-NF-κB and TBK1/IKK-i-IRF-3/IRF-7, which ends with the expression
of pro-inflammatory cytokines and type-I IFN.  Recognition of dsRNA could also be mediated by RIG-I and
occurs in the cytoplasm activating TBK1/IKK-i through the adapter protein IPS-1 located in the mitochondria
membrane.
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activation of the kinase complexes constituted by
inhibitor of kappaB (IκB) and IkappaB kinase (IκK)
and in the degradation of phosphorylated IκB6. Finally,
the nuclear factor κB (NF-κB), the activator protein 1
(AP-1), and the IFN regulatory factors (IRFs) are
released and translocated to the nucleus where regulate
the expression of molecules that participate in the
inflammatory response and in the initiation of innate
immunity4,7 (Figure 2).
The stimulation of TLR7 and TLR9 with their
respective ligand results in the formation of a complex
constituted by MyD88, IRAK-4, TRAF6, TRAF3,
IRAK-1, IKK-κ, and IRF7 responsible for the activation
of IRF7, which once phosphorylated is translocated to
the nucleus and regulates the expression of type-I IFN.
TLR3, through TRIF as adaptor protein, can induce the
phosphorylation of IRF3 translocated to the nucleus
and activates NF-κB and the expression of type-I IFN,
as described above4,6,7.
In summary, the stimulation of TLRs through viral
PAMPs  or another origin allows the recruitment of
adaptor proteins responsible for activating the induction
of signaling pathways that result in the activation of
transcriptional factors involved in the activation of the
expression of genes whose products are involved in
antiviral responses.
Recognition of viral components through TLRs.
TLRs are components of a PAMP recognition system
that act in concordance with other cellular factors to
establish a bridge between the innate response and the
adaptive immunity8. Their activation is initiated by a
signaling pathway that leads to the activation of some
mitogen-activated protein kinases (MAPKs) and of
transcription factors like AP-1, IRF, and NF-κB. These
transcription factors are responsible for the activation
of genes that encode pro-inflammatory cytokines, such
as the tumor necrosis factor α (TNF-α), interleukins
(IL-1, 6, 8, and 18), IFN-α/β, chemokines, leukotrienes,
class II major histocompatibility molecules and co-
stimulatory molecules like CD40, CD80, and CD86,
necessary for adequate antigenic presentation.
Initially, it was believed that the only TLRs involved
in recognition of viral PAMPs were those recognizing
nucleic acids like TLR3, TLR7/8, and TLR9, located in
acid endosomes. However, certain authors and our
unpublished results suggest that TLR2 and TLR4,
located on the cell surface and known to recognize
bacterial components, are also able to recognize viral
PAMPs, mainly envelope glycoproteins9,10. A study
carried out using TLR2 and MyD88-deficient mice
infected with Lymphocytic choriomeningitis virus
(LCMV) demonstrated that the TLR2-MyD88
interaction is essential for the activation of astrocytes
and microglia and for the production of TNF-α and the
monocyte chemo-attractant protein-1 (MCP-1)11. TLR2
also recognizes PAMPs from measles virus (MV),
hepatitis C virus (HCV) and human herpes simplex
virus type-1 and 2 (HSV1/2)12-14. In the case of HCV, it
was demonstrated that an increase in the level of
expression of TLR2 in individuals with chronic hepa-
titis is related to an increase in the level of circulating
TNF-α and to the development of hepatic lesions13. A
study performed in HEK293 cells stimulated with
Epstein-Barr virus (EBV) showed that TLR2 is
stimulated through NF-κB14,15. Acute infection by
varicella zoster virus (VZV) is characterized by the
development of an inflammatory response due to high
cytokine production, specifically IL-6 and IL-8, which
is associated with increased expression of TLR2 in
human monocytes exposed to the virus16.
TLR4 is stimulated by bacterial lipopolysaccharides
(LPSs) and endogenous ligands that are inflammation
products, such as fibrinogen, fibronectin, β-defensins,
and heat shock proteins7. Studies performed using
TLR4-deficient mice infected with vesicular stomatitis
virus (VSV) showed decreased expression of IL-12 and
a higher viral load in comparison to mice expressing
this receptor17. The role of TLRs in modulating the
replication of certain viruses has also been examined.
Using mice transgenic for Hepatitis B virus and
intravenously injected with specific ligands for TLR2,
3, 4, 5, 7, and 9 showed that all receptors, except TLR2,
can inhibit virus replication in IFN-dependent manner18.
In summary, TLR4 is stimulated by PAMPs from the
respiratory syncytial virus (RSV), coxsackie B virus,
HSV, and MV19-21. However, additional studies must
be pursued to determine the role of TLR2 and TLR4 in
viral infections and in antiviral defense.
All endosomal TLRs are activated by nucleic acids.
They also promote transcription of several cytokine
and chemokine coding genes through the activation of
NF-κB and MAPK, resulting in the expression of pro-
inflammatory cytokines6. The main ligands of TLR3
are double-stranded RNA (dsRNA) genomes, and
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dsRNA replication intermediates of single-stranded
RNA (ssRNA) viruses like RSV, dengue virus, and
encephalomyocarditis virus22. TLR3 is also activated
by contact with synthetic molecules or viral dsRNA
analogs [poly (I:C)]. The final product of TLR3
activation is the induction of a strong inflammatory
response characterized by the secretion of IL-12, TNF-
α, IL-6, CXCL-10, IL-10, and IFN-α.
The role of TLR3 in antiviral immune response was
demonstrated in TLR3-deficient mice, which are more
susceptible to murine cytomegalovirus (MCMV), given
lower expression of IFN23. TLR3-deficient mice infected
with West Nile virus (WNV) develop higher viral
loads24; however, the mice are less susceptible to
developing meningitis, suggesting that the entry of the
virus to the brain, and its pathogenesis, could be mediated
by TLR3 activation and the immune response developed
upon viral infection. TLR7 is also involved in antiviral
responses. In humans, TLR7 is mainly expressed by
plasmacytoid dendritic cells (pDCs), which after
stimulation, induce the activation of NF-κβ and MAPK
and trigger the expression of cytokines such as IL-6, IL-
12 and IFN-α, and the activation of co-stimulatory
molecules through the TLR7 pathway15.
TLR7 and TLR8 are tightly related endosomal
receptors and their ligands are ssRNAs. Both receptors
are also activated by guanine analogs and uridine or
guanosine-rich ssRNAs of either viral or cellular origin.
Both receptors are crucial for the development of
adaptive immune responses during viral infections, as
is the case with influenza virus and dengue virus15,25.
Finally, the endosomal TLR9 is activated by at least
three types of ligands with different biological out-
comes26: i) viral DNA, ii) conventional CpG-containing
DNA that activates B lymphocytes and induces the
production of inflammatory cytokines by macrophages,
and iii) D/A-type CpG containing-DNA that also stimu-
lates the production of cytokines by macrophages and B
lymphocytes, besides stimulating high production of
type-I IFN by pDCs. It has been reported that this is the
mechanism used by pDCs to respond through TLR9 to
the presence of DNA viruses, such as adenoviruses,
HSV1/2 and MCMV27-29. However, besides the recognition
of DNA by TLR9, a different TLR9-independent
mechanism has been proposed allowing the recognition of
dsDNA in the cytoplasm of macrophages and in non-
immune cells, but also inducing activation of IRF3,
NF-κβ, and IFN-α30.
Together, this shows that upon stimulation by nucleic
acids or viral proteins, TLRs induce the expression of
pro-inflammatory cytokines, whose function is to protect
the host from viral infection. Thus, type-I IFN is one of
the main components of innate immunity and is regulated
by signals initiated at both intracellular and extracellular
levels.
RLRs, adaptor molecules and their signaling
pathways. The RIG-I and the MAD5 are two RLRs that
recognize, respectively, short dsRNAs with 5’
triphosphate ends and long dsRNAs from viral genomic
RNAs. Both proteins are cytoplasmic and members of
the DExD/Hbox RNA helicases that are stimulated by
dsRNAs. RIG-I/MDA5 have two recruiting domains:
an RNA helicase domain and a caspase recruitment
domain (CARD; also known as caspase recruiting
domains). The first domain is responsible for the
recognition of dsRNAs and for the recruitment of
various proteins that activate signaling pathways, and
the CARD domain recruits proteins implicated in type-
I IFN expression31. An adaptor protein has been
described in this new signaling pathway. It is known as
IFN-α promoter stimulator (IPS-1), [or anti-viral
signaling protein (MAVS), virus-induced signaling
adaptor (VISA) or CARD adaptor inducing IFN-α
(Cardif)], and when it interacts with the CARD domain,
allows the recruitment of dsRNA, which results in the
expression of type-I IFN due to the activation and
translocation of IRF3, IRF7 and NF-κB to the
nucleus32,33. RIG-I is up or down regulated by the
ubiquitin ligase TRIM25 and by RNF125. This means
that RIG-I/MDA5 recognizes viral dsRNAs in the
cytoplasm, while TLR3 does so in the endosomes.
Recognition of viral components by RIG-I/MAD5:
RNA helicase-like receptors (RLRs). Certain viral
dsRNAs synthesized in the cytoplasm as viral life cycle
intermediaries, or as part of viral genomes are not only
recognized by TLR3, but also by RLRs such as RIG-I
and MAD5, which induce the expression of type-I IFN
through a signaling pathway independent of the signaling
activated by TLR3. Working with RIG-I- (RIG-I-/) and
MAD5- (MAD5-/-) deficient mice, it was demonstrated
that RIG-I is essential in recognizing RNAs from para-
myxoviruses, influenza virus, and Japanese encephalitis
virus; MAD5 is essential in recognizing picornavirus
RNA and for the expression of IFN34-36. These results
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show that RLRs recognize different types of viral
RNAs and activate a signaling pathway involved in the
expression of IFN, different from the pathway used by
TLRs. It was recently shown that cells over-expressing
RIG-I and stimulated by Newcastle disease virus (NDV)
or VSV present increased levels of expression of type-
I IFN; in contrast, cells with low-level expression of
RIG-I and stimulated by NDV, VSV, Sendai virus,
HCV, or WNV show decreased levels of IFN37.
Because RIG-I/MAD5α induces antiviral responses,
it has been suggested that the signaling pathways of
both proteins have a common adaptor protein, but it is
unclear whether they act in synergy when recognizing
viruses. However, MDA5 not only participates in
antiviral responses, it also inhibits the growth of tumor
cells, through type-I IFN34,35.
Effector proteins involved in viral PAMP
recognition. In the previous sections, the main PRRs
involved in the induction of antiviral responses upon
exposure to viral PAMPs were described. Nevertheless,
it is also worth mentioning some proteins encoded by
IFN-stimulated genes (ISGs). These proteins recognize
virus structural components and through diverse
mechanisms can activate antiviral responses. The first
effector protein described with such characteristics
was the PKR, which is an IFN-inducible serine-threonine
kinase, but in contrast to PRRs, its activation does not
regulate transcription, but blocks protein synthesis38.
PKR possesses two dsRNA-binding motifs (dsRBMs)
in its N-terminal region and a kinase motif in its C-
terminal region. As a monomer, PKR is inactive, but its
binding with dsRNA or highly structured RNAs indu-
ces its homodimerization and stimulates its autophos-
phorylation and auto-activation39. Once in the active
state, PKR is dissociated from the dsRNA and phos-
phorylates the α-subunit of the eukaryotic translation
initiation factor 2 (eIF2α), resulting in the inhibition of
cellular and viral protein synthesis. PKR can also be
stimulated by pro-inflammatory factors, such as growth
factors, cytokines38, or the PKR-activating protein
(PACT). In virus infected cells, most of the natural
PKR activators are viral dsRNAs or viral life cycle
replication intermediates. However, complex viruses
with DNA genomes like Vaccinia virus (VV), Adeno-
virus, HSV-1, or HSV-2 have open reading frames
(ORFs) in opposite orientation. This allows the produc-
tion of overlapping mRNA transcripts that result in the
production of dsRNAs that can in turn activate PKR.
Interfering RNA (RNAi) used to silence PKR, or PKR
knockout mice, has shown a reduction in their expression
affects IFN production upon WNV infection, making
the mice more susceptible40,41.
The presence of viral RNA also activates 2’-5’OAS,
also known as 2’5’ A synthetase. This enzyme is
activated by IFN and was initially described as regulator
of IFN synthesis, and, hence, as a key factor in antiviral
responses40,42. 2´5´OAS promotes the degradation of
viral RNA and catalyzes the synthesis of 2’5’ oliga-
denylates that activate the latent cellular RNase (RNAse
L)42.
ADAR1, 2, and 3 belong to another family of proteins
known as adenosine deaminase acting on RNA (ADAR).
ADAR1 is induced in response to IFN and has two
different isoforms: ADAR1p150 and ADAR1p110.
Recently, it was described that, in infected cells, den-
gue virus 2 (strain TSV01) activates the expression of
genes regulated by IFN, such as ADAR, PKR, and
2’5’OAS43. It has also been demonstrated that ADAR1
is responsible for editing the Hepatitis delta virus RNA,
independently of IFN stimulation44. However, one of
the most interesting aspects of ADAR is its participation
in the biogenesis of microRNA, which are non coding
RNAs implicated in the regulation of the expression of
genes, whose products participate in various cellular
processes. Additionally, it has been reported that
ADAR1-induced modifications are necessary for the
maturation of such RNAs45.
Recently, the stimulator of interferon gene (STING)
protein, a new adaptor molecule that induces the
expression of type-I IFN and plays a role in antiviral
response was described. STING has 5 possible
transmembrane domains; if STING is present in the
endoplasmic reticulum, it can activate both NF-κβ and
IRF3 and induce the expression of type-I IFN46,47.
Studies made with mouse embryonic fibroblasts that do
not express STING show that such cells are susceptible
to infection by viruses with negative polarity RNAs,
including VSV48.
Another mechanism of host-virus recognition is
through the Fv [or tripartite motif (TRIM)] protein.
Many proteins with such motifs have been described.
The different isoforms are produced by alternative
mRNA splicing and each variant codes for a unique
domain in its C-terminus. TRIM proteins, including
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TRIM5α that has in its C-terminal region the B30.2 or
SPRY motif, can down regulate replication of retro-
viruses, such as HIV-1 and Murine leukemia virus49.
On the other hand, some proteins members of the
GTPase family, known as MX, are involved in
recognition of viral proteins like the nucleocapsid,
which after being recognized change their cellular
location, affecting the production of new viral particles.
All these mechanisms demonstrate the existence of
a wide variety of strategies for pathogen recognition
and host protection upon viral infections. In summary,
effector proteins play antiviral roles through 4 different
mechanisms: i) arrest of protein synthesis, ii) degradation
of viral RNA, iii) adenosine deaminase enzymes play
an important role in converting adenosines to inosines
(AàI), inducing errors in translation, and iv) recognition
of viral proteins. However, some of these processes can
drastically affect cell viability and cause the induction
of apoptosis43. For this reason, the antiviral response
induced by these types of proteins is immediate and
observed only during the early stages of the infection,
before the activation of the adaptive immune response.
Role of TLRs in viral pathogenesis. As described in
this review, the aim of the recognition of viral PAMPs
by PRRs is to control infection and/or contribute to the
development of the adaptive immune response.
However, prolonged activation of the innate immunity
by TLRs can contribute to viral pathogenesis; for
example, in WNV-infected mice in which the activation
of TLR3 induces elevated production of TNF-α and IL-
6 involved in the development of an inflammatory state,
the permeabilization of the hematoencephalic barrier is
induced, allowing viral entry and resulting in greater
infection of the central nervous system24. Similarly, it
has been described that RSV induces the over-expression
of TLR3 and TLR4 that trigger an inflammatory state in
the respiratory mucosa of the infected individual, who
is rendered vulnerable to infections by other pathogens19.
In cells stimulated in vitro with specific TLR2, 3, 4,
5, 7, 8, and 9 ligands and infected with HIV-1, both
naïve and memory T CD4+ and T CD8+ lymphocytes
are activated. T CD8+ lymphocytes are activated and
begin to express CD69, which promotes their own
retention in lymphoid tissues, but T CD4+ cells lose the
ability to express CD69. Despite these phenotypic
changes, the cell population enters the cell cycle, but
grows poorly, and can even undergo apoptosis. These
results suggest that the systemic activation of TLRs
through diverse ligands favors immune activation,
effector cell sequestering, and T cell turnover. All these
events can contribute to the immune dysfunction caused
by HIV-1 and to the loss of T CD4+ lymphocytes in
chronic HV-1 infections50.
Applications of TLRs in immunotherapies for viral
disease control. Because TLRs are important for the
induction of the innate immune response, understanding
the molecular mechanisms involved in their activation
could contribute to the development of immune therapies
of vaccines, not only for viral diseases, but also for
sepsis, allergies, autoimmune diseases, and cancer.
TLR activation induces several different effects in
immune cells, such as cytokine production, the positive
regulation of co-stimulatory molecules like CD40,
CD80, and CD86; for pDCs, which when stimulated
through TLR9, induce IFN-α production. In this
instance, besides the antiviral effect of IFN, it also
influences the transport and clustering of pDCs51. This
phenomenon is indispensable for the stimulation of the
adaptive immune response in lymph nodes51.
Other studies also carried out with pDCs have
demonstrated that early stimulation (4 h post-
stimulation) with TLR7 agonists activates the antiviral
cell machinery. Furthermore, stimulation of TLR7 and
TLR8 with imiquimod and resiquimod, specific agonist,
respectively, have therapeutic effects in basal cell car-
cinoma, genital lesions, and other epithelial lesions,
generally associated with chronic human papillomavirus
(HPV) infections52; these compounds induce apoptosis
of HPV-infected cells and of other epithelial cells with
dysplasic or neoplasic changes.
Evasion of innate immunity by viruses. As a
consequence of the interaction between PRRs and
PAMPs, the signaling pathways activated result in
cytokine and IFN expression, or in the case of effector
proteins, in inhibition of protein synthesis or degradation
of viral dsRNAs. However, viruses has developed
strategies to evade or take advantage of such immuno-
logical barriers for productive infections. Among the
strategies already described is blockage of certain steps
in the synthesis of IFN-α/β, inactivation of secreted
IFN molecules, interference with signaling and/or
blockage of the activity of effector antiviral proteins
through their sequestration, production of viral homo-
logous proteins, or competition. In the following
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paragraphs, we briefly describe some of the cell
components manipulated by viruses to evade the innate
immune response.
Expression of type-I IFN depends on the activation
of IRF3 and IRF7 via IKK epsilon and TBK1. The
genome of Rabies virus, Borna disease virus, and Ebola
virus code for the P phosphoprotein and VP35 that can
block the antiviral response induced by IFN53-55. In
contrast, the human herpes simplex virus 8 encodes
different analogs of IRF with negative dominant activity,
allowing it to interfere with the activity of cellular
IRFs56. The infected cell polypeptide 0 (ICP0) from
Bovine herpes virus can interact with IRF3 and induce
its proteasome-dependent degradation57. Similarly, the
V protein of paramyxoviruses interacts with MD5-α
and inhibits IFN-α expression58.
The genome of VV encodes two proteins (A46 and
A52) that specifically inhibit the TLR-dependent
signaling pathway. A46 interacts with the adaptor
MyD88, TRIF and TRAM; while A52 interacts with
TRAF and IRAK-2, inhibiting the formation of the
complex implicated in the signaling pathway59. During
chronic infections, the NS3/4A protease of HCV degra-
des the TRIF adaptor of TLR3, resulting in an alteration
of the antiviral response induced by dsRNA. There is
also evidence regarding inhibition of PKR by viruses
via several pathways: VV E3L, Influenza virus NS1,
and Reovirus δ3 proteins can sequester dsRNAs and
prevent PKR activation. Other viruses express dsRNA
or highly structured RNAs that compete for binding to
PKR. EBER-1 and EBER-2, expressed during the latent
state of EBV and HCV IRES are some such examples40.
Inhibition of PKR can also result from protein-protein
interactions, as is the case of the HCV NS5 and VV E3L
that interact with PKR and inhibit its function40,41,55.
The transcription factor NF-κβ is key in the induction
of the IFN expression and of pro-inflammatory cytokines
involved in antiviral response. However, it can also be
beneficial for viruses, given that the promoters of some
viruses, including HIV-1, CMV, and EBV have binding
sites for NF-κβ, which facilitates transcription of the
viral genome. Hence, some viruses can up- or down-
regulate the NF-κκβ expression; for example, some
proteins of the African swine fever virus are able to
regulate its expression. In the early stages of infection,
the early viral protein A238L inhibits NF-κβ expression,
but once the infection progresses the late viral protein
A224L stimulates its expression60. Furthermore, besides
the direct strategies inhibiting IFN expression, VV
expresses the A52R protein, which contains a TIR
domain that interacts with the cytoplasmic proteins
IRAK-2 and TRAF6 involved in TLR signaling59.
Consequently, VV can affect the signaling induced by
TLRs and additionally reduce the extent of the antiviral
immune response.
CONCLUSIONS
The strategies used by vertebrates to recognize
viruses are similar to those used to recognize other
microorganisms, but for the former, the main PAMPs
are usually nucleic acids or glycoproteins. As a result,
screening of these molecules is performed in the same
cell compartment as described for the PAMPs of other
pathogenic agents. From this perspective, compartmen-
talization of the innate system has some similarity with
the adaptive immune system because both systems use
certain factors, depending on their cellular location. It
is clear; however, as shown here, that upon infection,
the immune response is initiated with the recognition of
viral PAMPs by PRRs, resulting in the up-regulation of
IFN-α/β. Since the discovery of IFN, 50 years ago,
knowledge about the signaling pathways that regulate
its production has greatly expanded. The discovery of
different PRRs has led to better understanding the
interactions between the innate and adaptive immune
responses and has favored the development of new
therapies owing to the discovery that the stimulation of
TLRs plays an important role in the protection from, or
in the development of diseases. This highlights the
importance of studies aiming to better understand the
regulatory mechanisms and the signaling pathways
associated with the PRRs in response to PAMPs.
Other molecules that have also gained importance
are the effector proteins, which inhibit protein synthesis,
degrade RNA, or modify viral genomes and are also
involved in launching the activation of the innate immune
system and in developing the adaptive immune response.
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